peptys



Размер файла: 2209.11 Кб | Скачиваний:  1  |  Загрузить
Ocoxin oral solution demonstrates antiviral properties in cellular models

(1,2) ATANASIO PANDIELLA (1,2),  EDUARDO SANZ, (3)  and  ELENA DÍAZ‑RODRÍGUEZ (1,2). 1 Institute of Molecular and Cellular Cancer Biology, Cancer Research Institute of Salamanca, Spanish Research Council‑Institute for Biomedical Research of Salamanca;  2 Spanish Cancer Research Biomedical Network (CIBERONC), 37007 Salamanca; 3 Catalysis S.L., 28016 Madrid, Spain. EXPERIMENTAL AND THERAPEUTIC MEDICINE  22:  1127,  2021

Размер файла: 2825.23 Кб | Скачиваний:  1  |  Загрузить
МНОГОКОМПОНЕНТНЫЙ НУТРИЦЕВТИК ОНКОКСИН И ЕГО ВЛИЯНИЕ НА КАЧЕСТВО ЖИЗНИ И ТОКСИЧНОСТЬ ПРОТИВООПУХОЛЕВОГО ЛЕЧЕНИЯ У ПАЦИЕНТОВ, ПОЛУЧАЮЩИХ АДЪЮВАНТНУЮ ХИМИОТЕРАПИЮ.

Кайдарова Д., Копп М., Покровский В., Джугашвили М., Акимжанова Ж., Абдрахманов, Р., Бабич Е., Билан Е., Бяхов А. Гуров С., Королёва И., Мочалова А., Повага С., Райгородский М., Сайфуллин А., Санз Е., Петровский Ф. Oncology Letters 2019 Vol.18


Размер файла: 924.35 Кб | Скачиваний:  1  |  Загрузить
Efficacy of Oncoxin-Viusid on the Reduction of Adverse Reactions to Chemotherapy and Radiotherapy in Patients Diagnosed with Cervical Cancer and Endometrial Adenocarcinoma

Raiza Ruiz Lorente (1), Daysi Hernández Durán (1), Jessica García Viamontes (1), Juan Lence Anta (2) Rosa Ortiz Reyes (2), Eduardo Sanz Navares (3). 1
Hospital “Ramón González Coro”, Havana, Cuba; 2 National Institute of Oncology and Radiobiology of Cuba, Havana, Cuba;  3 Laboratorios Catalysis S.L., Madrid, Spain. Journal of Cancer Therapy, 2020, 11, 276-295


Размер файла: 14188.98 Кб | Скачиваний:  2  |  Загрузить
Multicomponent nutritional supplement Oncoxin and its influence on quality of life and therapy toxicity in patients receiving adjuvant chemotherapy

Dilyara Radikovna Kaidarova (1), Mikhail Valeryevich Kopp (2), Vadim S Pokrovsky (3),  Maia Dzhugashvili (4) , Zhanna Mukhataevna Akimzhanova (5), Ramil Zufarovich Abdrakhmanov (1), Elena Nikolaevna Babich (6), Evgeniy Viktorovich Bilan (6), Anton Valeryevich Byakhov (7), Sergey Nikolaevich Gurov (8),Irina Albertovna Koroleva (2), Anastasiia Sergeevna Mochalova (9), Svetlana Sergeevna Povaga (10) , Maxim Vladimirovich Raigorodsky (11), Arthur Sidorovich Saifullin (12), Eduardo Sanz (13), Fedor Igorevich Petrovskiy (14). 1 Kazakh Research Institute of Oncology and Radiology, Almaty 050000, Republic of Kazakhstan;  2 Department of Clinical Medicine, Medical University ‘Reaviz’, Samara 443001; 3 Department of Biochemistry
N.N. Blokhin Cancer Research Center, RUDN University, Moscow 115478, Russia; 4 Department of Oncology Radiology Murcia University, Murcia 30200, Spain; 5 Department of Chemotherapy, Almaty Oncology Center, Almaty 050060, Republic of Kazakhstan; 6 Department of Oncology, Khanty‑Mansiysk Regional Clinical Hospital,  Khanty‑Mansiysk 628012; 7 Department of Chemotherapy, Moscow Clinical Scientific Center n. a. A.S. Loginov; Moscow 111123;
8 Department of Chemotherapy, Moscow Oncologic Clinical Dispensary No. 1, Moscow 105005; 9 Department of Chemotherapy, Clinical Hospital No. 1 MEDSI, Moscow 143442; 10 Department of Chemotherapy Russian Railways Hospital at The Station Smolensk, Smolensk 214025; 11 Department of Oncology, Medical Center ‘EVIMED’ LLC, Chelyabinsk 454048; 12 Department of Chemotherapy, Surgut Regional Hospital, 13 Surgut 628400, Russia;  
Scientific Department, Catalysis S.L., Madrid 28016, Spain;  14 Department of Pharmacology and Clinical Pharmacology, Khanty‑Mansiysk State Medical Academy, Khanty‑Mansiysk 628011, Russia. ONCOLOGY LETTERS  18:  5644-5652,  2019


Размер файла: 1280.19 Кб | Скачиваний:  3  |  Загрузить


Как с нами связаться?
    REVDI PM SIA
телефон:
э-почта:
адрес:
Рег.№ 40003423314
+371 67556696
info@revdi.lv
Католю 35, Рига, LV1003
----0